1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Patrys Limited

Patrys Limited

AASX:PAB
0.03
AUD
0.00
(0.00%)
0.00EPS
31.03MMarket Cap
Patrys Limited
ASX:PAB
(Australian Securities Exchange)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AUD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.02
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.06
0.04
0.02
0.01
0.01
- -
- -
- -
0.01
0.01
- -
0.01
0.01
- -
- -
- -
Book Value per Share
0.03
0.02
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
261
315
434
701
803
926
946
993
1,211
1,377
1,379
2,058
2,495
2,616
2,616
2,630
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-217,460.34
-121,760.34
-163,851.35
-202,146.8
- -
- -
- -
- -
-11,047.67
-15,550.92
-12,878.8
-19,717.68
-36,850.87
- -
- -
- -
Operating Margin (%)
1
1
2
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-8
-7
-5
-4
-7
-8
-1
-1
-2
- -
-3
-4
-7
-7
-4
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-161,906.38
-97,666.4
-105,316.24
-133,526.11
- -
- -
- -
- -
-9,080.92
-1,495.73
-9,994.69
-14,774.25
-24,655.87
- -
- -
- -
Profit Margin (%)
7
4
5
4
6
3
3
2
7
7
4
12
13
6
3
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
15
13
12
11
12
4
4
3
7
7
5
12
13
7
3
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-45.74
-51.72
-39.43
-30.4
-62.82
-103.27
-28.41
-33.58
-50.17
-5.64
-45.15
-48.02
-53.24
-69.69
-68.67
-143.39
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.67%
-3.77%
-78.88%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
58.55%
10.82%
-14.86%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Patrys Limited Patrys Limited (ASX:PAB) develops novel antibody technologies targeting cancer and NETosis-driven inflammatory diseases through its proprietary deoxymab platform of cell-penetrating antibodies; key assets include PAT-DX1 (Deoxymab 3E10), a lead candidate for primary and secondary brain cancers, metastases, and combination therapies with DNA-damaging agents such as radiation and chemotherapy; and PAT-DX3, a full-sized antibody variant with distinct tissue distribution and pharmacokinetic properties optimized for enhanced therapeutic delivery. The company, founded in 2006 and headquartered in Melbourne, Australia, at Suite 2, Level 11, 385 Bourke Street, operates primarily in the biotechnology sector with a focus on oncology and immunology, leveraging an exclusive worldwide license from Yale University secured in 2016 for deoxymab applications; it maintains a wholly-owned subsidiary, Nucleus Therapeutics Pty Ltd, and pursues preclinical and clinical advancement across Australia and the United States. Recent developments encompass receipt of an R&D tax incentive refund of $1.285 million by Nucleus Therapeutics in December 2024; completion of a non-renounceable pro-rata entitlement offer raising up to $1.77 million; successful GMP production of PAT-DX1 by its contract development and manufacturing organization in early 2024 ahead of first-in-human clinical studies; and an Australian patent grant for the Deoxymab platform conjugated to nanoparticles for targeted anti-cancer drug delivery, alongside preclinical data demonstrating PAT-DX1-NP's ability to cross the blood-brain barrier for triple-negative breast cancer brain metastases.